NASDAQ:ORTX Orchard Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orchard Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.17 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$4.99Now: $5.17▼$5.2550-Day Range$4.66MA: $5.18▼$6.4552-Week Range$4.44Now: $5.17▼$15.93Volume496,131 shsAverage Volume570,082 shsMarket Capitalization$502.85 millionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingOrchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.33, Orchard Therapeutics has a forecasted upside of 293.3% from its current price of $5.17.Amount of Analyst CoverageOrchard Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesOrchard Therapeutics has received 134 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrchard Therapeutics has received 163 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrchard Therapeutics has received 54.88% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote “Outperform” if you believe ORTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrchard Therapeutics does not currently pay a dividend.Dividend GrowthOrchard Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Orchard Therapeutics is held by insiders.Percentage Held by Institutions70.03% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.84) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchard Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchard Therapeutics is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchard Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORTX Previous Symbol CUSIPN/A CIKN/A Webwww.orchard-tx.com Phone011-44-0-203-3846700Debt Debt-to-Equity Ratio0.11 Current Ratio6.07 Quick Ratio6.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.51 million Price / Sales200.34 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book1.66Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-163,420,000.00 Net MarginsN/A Return on Equity-63.77% Return on Assets-48.60%Miscellaneous Employees180 Outstanding Shares97,264,000Market Cap$502.85 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $5.17 0.00 (0.00 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ORTX News and Ratings via Email Sign-up to receive the latest news and ratings for ORTX and its competitors with MarketBeat's FREE daily newsletter. Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions How has Orchard Therapeutics' stock price been impacted by COVID-19? Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ORTX stock has decreased by 43.1% and is now trading at $5.17. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Orchard Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Orchard Therapeutics. When is Orchard Therapeutics' next earnings date? Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Orchard Therapeutics. How were Orchard Therapeutics' earnings last quarter? Orchard Therapeutics PLC - (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.05. The business had revenue of $0.60 million for the quarter. View Orchard Therapeutics' earnings history. What price target have analysts set for ORTX? 3 Wall Street analysts have issued twelve-month price objectives for Orchard Therapeutics' stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate Orchard Therapeutics' share price to reach $20.33 in the next twelve months. This suggests a possible upside of 293.3% from the stock's current price. View analysts' price targets for Orchard Therapeutics. Are investors shorting Orchard Therapeutics? Orchard Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,670,000 shares, an increase of 35.5% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 972,100 shares, the short-interest ratio is presently 2.7 days. Currently, 3.2% of the company's stock are sold short. View Orchard Therapeutics' Short Interest. Who are some of Orchard Therapeutics' key competitors? Some companies that are related to Orchard Therapeutics include BAVARIAN NORDIC/S (BVNRY), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Coherus Biosciences (CHRS), Adaptimmune Therapeutics (ADAP), Compugen (CGEN), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Alector (ALEC), Translate Bio (TBIO), I-Mab (BDTX) and Replimune Group (REPL). View all competitors. What other stocks do shareholders of Orchard Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), NGM Biopharmaceuticals (NGM), Tesla (TSLA) and Xeris Pharmaceuticals (XERS). Who are Orchard Therapeutics' key executives? Orchard Therapeutics' management team includes the following people: Mr. Mark A. Rothera, CEO, Pres & Director (Age 56)Dr. Anne Dupraz-Poiseau, Chief Regulatory OfficerMr. Frank E. Thomas, CFO & Chief Bus. Officer (Age 49)Ms. Ran Zheng, Chief Technical OfficerProf. Bobby Gaspar Ph.D., M.D., Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 54) When did Orchard Therapeutics IPO? (ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Orchard Therapeutics' stock symbol? Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX." Who are Orchard Therapeutics' major shareholders? Orchard Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (7.46%), CHI Advisors LLC (3.01%), CHI Advisors LLC (3.01%), Federated Hermes Inc. (2.76%), Regents of The University of California (0.88%) and ArrowMark Colorado Holdings LLC (0.45%). View institutional ownership trends for Orchard Therapeutics. Which major investors are selling Orchard Therapeutics stock? ORTX stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, ArrowMark Colorado Holdings LLC, Driehaus Capital Management LLC, CHI Advisors LLC, CHI Advisors LLC, Artal Group S.A., Nuveen Asset Management LLC, and Two Sigma Advisers LP. View insider buying and selling activity for Orchard Therapeutics. Which major investors are buying Orchard Therapeutics stock? ORTX stock was purchased by a variety of institutional investors in the last quarter, including Regents of The University of California, Federated Hermes Inc., Platinum Investment Management Ltd., California Public Employees Retirement System, Goldman Sachs Group Inc., Mutual of America Capital Management LLC, Marshall Wace LLP, and Trexquant Investment LP. View insider buying and selling activity for Orchard Therapeutics. How do I buy shares of Orchard Therapeutics? Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Orchard Therapeutics' stock price today? One share of ORTX stock can currently be purchased for approximately $5.17. How big of a company is Orchard Therapeutics? Orchard Therapeutics has a market capitalization of $502.85 million and generates $2.51 million in revenue each year. The company earns $-163,420,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Orchard Therapeutics employs 180 workers across the globe. What is Orchard Therapeutics' official website? The official website for Orchard Therapeutics is www.orchard-tx.com. How can I contact Orchard Therapeutics? Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700. This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
